Eiropas Savienība - itāļu - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - ritonavir - infezioni da hiv - antivirali per uso sistemico - ritonavir è indicato in combinazione con altri agenti antiretrovirali per il trattamento di pazienti con infezione da hiv-1 (adulti e bambini di due anni di età e oltre).

Eiropas Savienība - itāļu - EMA (European Medicines Agency)

gilead sciences ireland uc - elvitegravir, cobicistat, emtricitabina, tenofovir disoproxil fumarato - infezioni da hiv - antivirals for treatment of hiv infections, combinations, antivirals for systemic use - trattamento del virus dell'immunodeficienza umana 1 (hiv-1) infezione in adulti età compresa tra 18 anni e oltre che sono naïve al trattamento antiretrovirale o sono infettate con hiv 1 senza mutazioni note associate a resistenza ad uno qualsiasi dei tre agenti antiretrovirali in stribild.

Eiropas Savienība - itāļu - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - infezioni da hiv - antivirali per uso sistemico - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Eiropas Savienība - itāļu - EMA (European Medicines Agency)

janssen-cilag international n.v. - o esposti per lungo tempo, cobicistat - infezioni da hiv - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - rezolsta, è indicato in associazione con altri medicinali antiretrovirali per il trattamento dell'infezione da virus dell'immunodeficienza umana 1 (hiv 1) negli adulti di età pari o superiore a 18 anni. genotipica test devono guidare l'uso di rezolsta.

Itālija - itāļu - AIFA (Agenzia Italiana del Farmaco)

teva italia s.r.l. - darunavir - darunavir

Itālija - itāļu - AIFA (Agenzia Italiana del Farmaco)

accord healthcare, s.l.u. - ritonavir - ritonavir

Šveice - itāļu - Swissmedic (Swiss Agency for Therapeutic Products)

hra-pharma switzerland sàrl - metyraponum - capsule - metyraponum 250.00 mg, macrogolum 400, glycerolum (85 per centum), aqua purificata, macrogolum 4000, kapselhülle: gelatina, glycerolum (85 per centum), e 171, e 215 0.71 mg, ethylvanillinum, propylis parahydroxybenzoas natricus 0.35 mg, 4-methoxyacetophenonum, drucktinte: e 120, aluminii chloridum hexahydricum, natrii hydroxidum, hypromellosum, propylenglycolum, pro capsula corresp. natrium 0.13 mg. - adrenocorticostaticum - synthetika

Šveice - itāļu - Swissmedic (Swiss Agency for Therapeutic Products)

streuli pharma ag - prednisolonum - compresse - prednisolonum 5 mg, isomaltum 93 mg, amylum pregelificatum, carboxymethylamylum natricum corresp. natrium 0.3 mg, magnesii stearas pro compresso. - glukokortikosteroid-therapie - synthetika

Šveice - itāļu - Swissmedic (Swiss Agency for Therapeutic Products)

streuli pharma ag - prednisolonum - compresse - prednisolonum 20 mg, isomaltum 77.94 mg, amylum pregelificatum, carboxymethylamylum natricum corresp. natrium 0.3 mg, magnesii stearas, e 132 pro compresso. - glukokortikosteroid-therapie - synthetika

Šveice - itāļu - Swissmedic (Swiss Agency for Therapeutic Products)

streuli pharma ag - prednisolonum - compresse - prednisolonum 50 mg, isomaltum 194.86 mg, amylum pregelificatum, carboxymethylamylum natricum corresp. natrium 0.9 mg, magnesii stearas, e 127 pro compresso. - glukokortikosteroid-therapie - synthetika